Trial Profile
An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody,IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 10 Sep 2019 Results of exploratory analysis by using data from four studies (KEYNOTE-189, PARAMOUNT, PRONOUNCE, and JVBL) presented at the 20th World Conference on Lung Cancer.
- 17 May 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 This trial has been completed in Belgium (end date: 2018-04-19)